Changing indications for liver transplant: slow decline of hepatitis viruses in Italy

References

• Kondili LA, Robbins S, Blach S, et al. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018;38(12):2190–2198.
   PubMed Web of Science ®Google Scholar
• Andreone P, Di Marco V, Gaeta GB, et al. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: assessment of an Italian focus group. Dig Liver Dis. 2019;51(7):915–921.
   PubMedGoogle Scholar
• Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9(6):e026726.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Stroffolini T, Sagnelli C, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. Dig Liver Dis. 2016;48(9):1066–1071.
   PubMedGoogle Scholar
• Stroffolini T, Trevisani F, Pinzello G, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875–880.
   PubMedGoogle Scholar
• Bucci L, Garuti F, Lenzi B, et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2017;37(2):259–270.
   PubMed Web of Science ®Google Scholar
• Italian Medicine Agency (AIFA). [cited 2019 Nov 09]. Available from: http://www.agenziafarmaco.gov.it/
   Google Scholar
• Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69(4):810–817.
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356–1358.
   PubMed Web of Science ®Google Scholar
• Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry Study. J Hepatol. 2019;71(2):313–322.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Fasano M, Grossi A, et al. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071–1076.
   PubMed Web of Science ®Google Scholar
• Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79–84.
   PubMed Web of Science ®Google Scholar
• Ferrarese A, Germani G, Gambato M, et al. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: a single-center study. WJG. 2018;24(38):4403–4411.
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Nardi A, Madonia S, et al. The present profile of chronic hepatitis B virus infection highlights future challenges: an analysis of the Multicenter Italian MASTER-B cohort. Dig Liver Dis. 2019;51(3):438–442.
   PubMedGoogle Scholar
• Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013;58(2):287–296.
   PubMed Web of Science ®Google Scholar
• Farci P, Niro AG. Current and future mamagement of chronic hepatitis D. Gastroenterol Hepatol (NY). 2018;14:342–351.
   PubMedGoogle Scholar
• Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–1659.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–838.
   PubMed Web of Science ®Google Scholar
• Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–735.
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NASH disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904.
   PubMed Web of Science ®Google Scholar
• Rapporto ISTISAN;19/5. [cited 2019 Nov 9]. Available from: www.epicentro.iss.it/alcol/apd2019/istisan-19_5_web.pdf
   Google Scholar
• Bucci L, Garuti V, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43(3):385–399.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2). DOI:10.1128/CMR.00046-19
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents. 2019;54(6):697–701.
   PubMed Web of Science ®Google Scholar